Continental Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Continental Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-305,400	Closed	-$3.19M	–	47
2023 Q4	$3.19M	Buy	305,400 +150,000	+97%	+$1.4M	1.24%	26
2023 Q3	$1.59M	Sell	155,400 -101,600	-40%	-$946K	0.84%	36
2023 Q2	$1.94M	Buy	257,000 +105,400	+70%	+$855K	0.87%	35
2023 Q1	$1.34M	Buy	151,600 +1,600	+1%	+$15.8K	0.72%	35
2022 Q4	$1.37M	Sell	150,000 -94,500	-39%	-$825K	0.72%	45
2022 Q3	$1.97M	Hold	244,500	–	–	1.16%	36
2022 Q2	$1.84M	Hold	244,500	–	–	1.11%	35
2022 Q1	$2.29M	Sell	244,500 -120,200	-33%	-$1M	1.13%	33
2021 Q4	$2.92M	Sell	364,700 -45,500	-11%	-$411K	1.23%	28
2021 Q3	$4M	Buy	410,200 +122,700	+43%	+$1.15M	1.69%	26
2021 Q2	$2.85M	Buy	287,500 +95,500	+50%	+$1.01M	1.31%	25
2021 Q1	$2.22M	Buy	192,000 +162,000	+540%	+$1.86M	1.03%	37
2020 Q4	$290K	Sell	30,000 -40,000	-57%	-$383K	0.13%	71
2020 Q3	$631K	Buy	+70,000	New	+$741K	0.33%	71
2019 Q4	–	Sell	-40,000	Closed	-$275K	–	77
2019 Q3	$275K	Hold	40,000	–	–	0.16%	71
2019 Q2	$369K	Buy	+40,000	New	+$482K	0.21%	69
2019 Q1	–	Sell	-140,000	Closed	-$2.16M	–	97
2018 Q4	$2.16M	Hold	140,000	–	–	0.66%	62
2018 Q3	$3.02M	Sell	140,000 -50,000	-26%	-$1.16M	0.66%	56
2018 Q2	$4.62M	Hold	190,000	–	–	1.15%	35
2018 Q1	$3.25M	Sell	190,000 -120,000	-39%	-$2.34M	0.82%	46
2017 Q4	$5.88M	Buy	310,000 +20,000	+7%	+$301K	1.27%	22
2017 Q3	$5.1M	Buy	290,000 +220,000	+314%	+$4.95M	1.17%	26
2017 Q2	$2.33M	Buy	70,000 +20,000	+40%	+$619K	0.52%	64
2017 Q1	$1.6M	Buy	+50,000	New	+$1.71M	0.36%	75
2014 Q1	–	Sell	-41,000	Closed	-$1.64M	–	146
2013 Q4	$1.64M	Sell	41,000 -75,000	-65%	-$2.95M	0.36%	79
2013 Q3	$4.38M	Sell	116,000 -36,300	-24%	-$1.42M	1.09%	22
2013 Q2	$5.97M	Buy	+152,300	New	+$5.93M	1.68%	14

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Continental Advisors's TEVA Position: Q1 2026 in Review

Continental Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 16% in Q1 2026, selling an estimated $1.48M and leaving 242,118 shares worth $7.29M. The position accounts for 3.72% of the portfolio, ranked #5.

Continental Advisors first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $8.99M in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Continental Advisors held 242,118 shares of Teva Pharmaceuticals worth $7.29M as of Q1 2026.
Continental Advisors sold 46,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $1.48M.
Teva Pharmaceuticals made up 3.72% of Continental Advisors's portfolio in Q1 2026, its #5 holding.
Continental Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Continental Advisors's Teva Pharmaceuticals position peaked at $8.99M in Q4 2025.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Continental Advisors's 13F filing for Q1 2026, filed 15 May 2026.